327 related articles for article (PubMed ID: 29781323)
41. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Robak P; Robak T
Expert Opin Investig Drugs; 2017 Nov; 26(11):1249-1265. PubMed ID: 28942659
[TBL] [Abstract][Full Text] [Related]
42. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
43. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
44. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
[TBL] [Abstract][Full Text] [Related]
45. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
46. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
47. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
[TBL] [Abstract][Full Text] [Related]
48. Ibrutinib and indolent B-cell lymphomas.
Akinleye A; Furqan M; Adekunle O
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
[TBL] [Abstract][Full Text] [Related]
49. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
50. Ibrutinib.
Charalambous A; Schwarzbich MA; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
[TBL] [Abstract][Full Text] [Related]
51. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Kienle DL; Stilgenbauer S
Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
[TBL] [Abstract][Full Text] [Related]
52. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
53. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
54. Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA; Woyach JA
Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
[TBL] [Abstract][Full Text] [Related]
55. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
56. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Battistello E; Katanayeva N; Dheilly E; Tavernari D; Donaldson MC; Bonsignore L; Thome M; Christie AL; Murakami MA; Michielin O; Ciriello G; Zoete V; Oricchio E
Blood; 2018 May; 131(21):2345-2356. PubMed ID: 29567799
[TBL] [Abstract][Full Text] [Related]
57. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
58. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
60. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Rhodes J; Mato A; Sharman JP
Curr Oncol Rep; 2018 Apr; 20(6):49. PubMed ID: 29644450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]